Colorectal cancer presents via multiple different clinical phenotypes that can arise from a variety of different genetic and molecular alterations. The aim of this study was to describe survival outcomes and treatment patterns of metastatic colorectal cancer (mCRC) patients by v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation status. The Alberta Cancer Registry was used to identify all patients >18 years old who had been diagnosed with mCRC in Alberta between 1 January 2017 and 31 December 2019 and had received at least one cycle of systemic therapy. Treatment patterns were compared between wild-type and mutantBRAFmCRC patients. Cox regression models and Kaplan–Meier curves were created to assess survival differences by both treatment pattern andBRAFstatus. A total of 488 patients were identified with mCRC, of which 42 (11.4%) were confirmed to have aBRAFmutation. The most common first-line treatment regimen was either capecitabine and oxaliplatin (CAPOX) or leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin (FOLFOX). The median overall survival for mCRC patients was 20.01 months. MutantBRAFpatients had a median survival of 8.21 months compared to 20.03 months among those with wild-typeBRAF.BRAFmutations among mCRC patients are associated with a considerably poor prognosis, reinforcing the need for clinicalBRAFtesting among newly diagnosed patients to better understand their prognosis.
结直肠癌通过多种不同的临床表型呈现，这些表型可由多种不同的遗传和分子改变引起。本研究旨在根据v-raf鼠肉瘤病毒癌基因同源物B1（BRAF）突变状态，描述转移性结直肠癌（mCRC）患者的生存结果和治疗模式。通过阿尔伯塔癌症登记处，识别了2017年1月1日至2019年12月31日期间在阿尔伯塔省诊断为mCRC、年龄大于18岁且至少接受过一个周期全身治疗的所有患者。比较了野生型和突变型BRAF mCRC患者的治疗模式。采用Cox回归模型和Kaplan-Meier曲线评估不同治疗模式和BRAF状态下的生存差异。共识别出488例mCRC患者，其中42例（11.4%）确认存在BRAF突变。最常见的一线治疗方案为卡培他滨联合奥沙利铂（CAPOX）或亚叶酸钙、氟尿嘧啶联合奥沙利铂（FOLFOX）。mCRC患者的中位总生存期为20.01个月。突变型BRAF患者的中位生存期为8.21个月，而野生型BRAF患者为20.03个月。mCRC患者的BRAF突变与显著不良预后相关，这强调了在新诊断患者中进行临床BRAF检测的必要性，以更好地了解其预后。
肿瘤(癌症)患者之家